Indication
Non-segmental Vitiligo
6 clinical trials
8 products
Clinical trial
A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-6194 in Adult Participants With Non-Segmental VitiligoStatus: Recruiting, Estimated PCD: 2025-09-11
Product
PlaceboProduct
MK-6194Product
RuxolitinibClinical trial
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2): A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With VitiligoStatus: Completed, Estimated PCD: 2021-03-15
Product
VehicleProduct
AS012Clinical trial
A Phase II, Randomized, Double Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of AS012 in Subjects With Non-segmental VitiligoStatus: Completed, Estimated PCD: 2022-05-20
Clinical trial
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1): A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With VitiligoStatus: Completed, Estimated PCD: 2021-03-18
Clinical trial
The Evaluation of Vitiligous Lesions Repigmentation After Topical Administration of Methotrexate in Patients With Active VitiligoStatus: Completed, Estimated PCD: 2023-06-01
Product
1% MethotrexateProduct
0.5% MethotrexateClinical trial
Latanoprost Plus NB-UVB Versus Each Alone in Non-segmental Vitiligo: Clinical and Laboratory EvaluationStatus: Active (not recruiting), Estimated PCD: 2024-02-13
Product
Latanoprost